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Summary
A mutation in the LMNA gene is responsible for the most dra-
matic form of premature aging, Hutchinson–Gilford progeria
syndrome (HGPS). Several recent studies have suggested that
protein products of this gene might have a role in normal physi-
ological cellular senescence. To explore further LMNA’s possible
role in normal aging, we genotyped 16 SNPs over a span of
75.4 kb of the LMNA gene on a sample of long-lived individuals
(LLI) (US Caucasians with age ‡ 95 years, N = 873) and geneti-
cally matched younger controls (N = 443). We tested all common
nonredundant haplotypes (frequency ‡ 0.05) based on sub-
groups of these 16 SNPs for association with longevity. The most
significant haplotype, based on four SNPs, remained significant
after adjustment for multiple testing (OR = 1.56, P = 2.5 · 10)5,
multiple-testing-adjusted P = 0.0045). To attempt to replicate
these results, we genotyped 3448 subjects from four indepen-
dent samples of LLI and control subjects from (i) the New Eng-
land Centenarian Study (NECS) (N = 738), (ii) the Southern Italian
Centenarian Study (SICS) (N = 905), (iii) France (N = 1103), and
(iv) the Einstein Ashkenazi Longevity Study (N = 702). We repli-
cated the association with the most significant haplotype from
our initial analysis in the NECS sample (OR = 1.60, P = 0.0023),
but not in the other three samples (P > 0.15). In a meta-analysis
combining all five samples, the best haplotype remained signifi-
cantly associated with longevity after adjustment for multiple
testing in the initial and follow-up samples (OR = 1.18,
P = 7.5 · 10)4, multiple-testing-adjusted P = 0.037). These results
suggest that LMNA variants may play a role in human lifespan.
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Introduction
Single gene mutations have been shown to extend the lifespan of worms,
yeast, and mice (Kenyon, 2005). Similarly, twin studies have shown that
25–30% of the variance in human lifespan can be attributed to genetic
differences (Herskind et al., 1996; Ljungquist et al., 1998; Skytthe et al.,
2003). With the completion of the International HapMap Project, power
to detect common variants for common and complex diseases has
increased (Manolio et al., 2008), and the search for genetic contributors
to human aging and lifespan has been accelerated. The results thus far
have been somewhat discouraging: only APOE and FOXO3A have been
consistently associated with longevity across populations in candidate
gene studies (Christensen et al., 2006; Novelli et al., 2008). Even strong
candidates such as the WRN gene associated with the premature aging
syndrome, Werner syndrome (Castro et al., 2000), have displayed incon-
sistent results (Christensen et al., 2006). Similarly, all longevity-associated
SNPs reaching genome-wide significance in two recently published gen-
ome-wide association studies were associated with the APOE gene (Dee-
len et al., 2011; Nebel et al., 2011). However, because variants with
subtler associations with longevity will not be detectable at genome-wide
significance levels with conventional sample sizes, candidate gene studies
remain a useful approach.
One major candidate gene for longevity that has not yet been explored
is LMNA. Defects in the LMNA gene, which encodes the nuclear envelope
proteins lamin A and lamin C, have been associated with at least 13 dis-
eases, including Hutchinson–Gilford progeria syndrome (HGPS) (Gruen-
baum et al., 2005; Capell & Collins, 2006). HGPS is a rare but devastating
condition in which symptoms resembling premature aging appear at a
very young age, typically within a year of birth. Owing to accelerated car-
diovascular disease leading to eventual heart attack or stroke, individuals
with HGPS have an average life expectancy of 13 years (Capell et al.,
2007; Merideth et al., 2008).
Scientists have long questioned whether HGPS is truly a model of nor-
mal human aging. Although displaying many features typically associated
with normal aging (alopecia, skin wrinkling, atherosclerosis), HGPS appar-
ently lacks other common features such as tumors or dementia. However,
recent evidence obtained since the identification of mutations in LMNA
as the cause of HGPS suggests that there may in fact be a molecular rela-
tionship. For example, there is evidence that a very small amount of the
mutant lamin A protein produced in HGPS, termed ‘progerin’, is pro-
duced in normal cells (Scaffidi & Misteli, 2006; Cao et al., 2007). Levels of
the progerin transcript increase with age in normal cells (Rodriguez et al.,
2009), and work using a monoclonal antibody specific for progerin has
demonstrated that progerin accumulates in human skin in an age-depen-
dent manner (McClintock et al., 2007). Further work in normal human
fibroblasts has demonstrated that progerin production is activated by
progressive telomere damage during cellular senescence (Cao et al.,
2011). Finally, it has been established that numerous other abnormalities
present in HGPS are also common in cells from aged individuals. These
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include nuclear blebbing, particular epigenetic changes, and increased
levels of DNA damage. Most remarkably, suppressing the production of
the mutant progerin protein through the use of an antisense morpholino
reversed all of these abnormalities in cell culture (Scaffidi & Misteli, 2006).
The corollary to this observation is the possibility that variants of LMNA
that produce less progerin might be protective and thus promote a longer
lifespan. To investigate further the potential links of HGPS, LMNA, and
progerin with the normal aging process, we sought to determine whether
common variants in the LMNA gene might be associated with extreme
human longevity. Toward this end, we tested variants of the LMNA gene
for association with extreme longevity in five independent samples of
long-lived individuals (LLI) and control subjects.
Results
Characteristics of the five study samples are shown in Table 1. In
the Stage 1 sample (US Caucasians with age ‡ 95 years, N = 873 and
genetically matched younger controls, N = 443), we genotyped 16 SNPs
covering two coherent linkage disequilibrium (LD) blocks, corresponding
to the LMNA gene and promoter region (Fig. 1). A total of 2414 nonre-
dundant haplotypes (i.e., haplotypes not in perfect LD with another hap-
lotype) involving 2–16 SNPs were present with estimated frequency
‡ 0.05 in our Stage 1 analysis. We tested all SNPs and all 2414 haplotypes
for association with longevity. SNP 6 showed the strongest single-SNP
association (P = 0.0137) in Stage 1, but was not significant upon correc-
tion for multiple testing via permutation tests. However, an excess of sig-
nificant haplotypes over what is expected under no association was
evident. We examined the proportion of haplotypes that were significant
at a range of significance thresholds (a = 0.00005, 0.0001, 0.0005,
0.001, 0.005, 0.01, and 0.05) and in all cases observed significantly more
than expected under no association. P-values for association tests of each
of these haplotypes are plotted against their quantiles in Fig. S1 (Support-
ing Information). The most significant haplotype, involving SNPs 6, 7, 13,
and 15 (GTCT), remained significant after adjustment for multiple testing
via permutation tests (P = 2.5 · 10)5, multiple-testing-adjusted
P = 0.0045). Haplotypes involving SNPs 4 and 5 were also significant, and
the most significant 6-SNP haplotype involved SNPs 4, 5, 6, 7, 13, and 15
(GAGTCT) (P = 4.0 · 10)5). One hundred and forty nonredundant haplo-
types involving different combinations of 2–6 of these six SNPs were pres-
ent with estimated frequency > 0.05.
To follow up on these 140 haplotypes, we selected SNPs 4, 5, 6, 7, 13,
and 15 for genotyping in our four Stage 2 samples (Table 1). One of the
six SNPs was not successfully genotyped in the French sample, but for
purposes of haplotype inference, we were able to impute genotypes for
this SNP using MaCH 1.0 (Li et al., 2010) in conjunction with phased hap-
lotype information from the HapMap CEU sample (estimated r2 between
true underlying genotype and imputed genotype = 0.97). Additional
LMNA SNPs beyond SNPs 4, 5, 6, 7, 13, and 15 were also genotyped
based on convenience and were included in the SNP association analysis
in Table 2 but not the haplotype analysis. SNP association results for all
Table 1 Samples tested
Sample N Age range Mean age
Stage 1 (US) 873 LLI ‡ 95 101.5
443 controls < 50 38.6
NECS (US) 545 LLI 96–113 103.2
193 controls 55–92 76.8
French 557 LLI ‡ 99 103.1
546 controls 18–70 51.2
SICS (Southern Italy) 455 LLI 90–109 97.6
450 controls 18–46 32.9
Ashkenazi Jewish 354 LLI 95–109 97.9
348 controls 43–90 70.7
LLI, long-lived individuals; NECS, New England Centenarian Study; SICS,
Southern Italian Centenarian Study.
Fig. 1 Linkage disequilibrium (R2 in HapMap CEU sample) between SNPs in LMNA region. Labeled SNPs indicate SNPs tested in Table 2. Encircled SNP names indicate SNPs
involved in GTCT haplotype in Table 3.
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five samples are shown in Table 2. When we combined results across
samples, SNP 15 showed the strongest single-SNP association in the
meta-analysis (OR = 1.17, P = 0.0056) with odds ratios ranging from
1.09 to 1.22 in the four samples tested, but was not significant after cor-
rection for multiple testing via permutation tests (multiple-testing-
adjusted P = 0.105).
In replication analyses of the 140 haplotypes of SNPs 4, 5, 6, 7, 13, and
15 in the four Stage 2 samples, an excess of significant haplotypes was
observed in the New England Centenarian Study (NECS) sample (Fig. S2;
P < 0.01, Supporting information) for all significance thresholds exam-
ined (a = 0.00005, 0.0001, 0.0005, 0.001, 0.005, 0.01, and 0.05), but
not in the other three Stage 2 samples. When the results for all 140
followed-up haplotypes were combined across all five samples in a meta-
analysis (Table 3 and Fig. 2), the original GTCT haplotype of SNPs 6, 7,
13, and 15 was again the most significant (P = 7.5 · 10)4) and remained
significant after permutation-based adjustment for multiple testing in
both stages of the analysis (multiple-testing-adjusted P = 0.037).
If the genetic load is greater for older individuals, restricting the defini-
tion of LLI to include only centenarians should lead to a stronger genetic
effect (Tan et al., 2008). For the four samples whose age and sex infor-
mation was available [Stage 1, NECS, Southern Italian Centenarian Study
(SICS), and the Ashkenazi sample], we reperformed the association test
for the GTCT haplotype within each sample after restricting the definition
of LLI to include individuals with age ‡ 100. However, the odds ratio for
GTCT did not change substantially in any of the four samples. We also
performed a sex-stratified version of the haplotype analysis. Similar results
were observed in the sex-stratified analysis for each sample, and results
were similar for men and women within each sample.
The Stage 1 sample had previously been tested for the presence of pop-
ulation stratification between LLI and control subjects (see Supporting
information) (Geesaman et al., 2003). However, to ensure that the asso-
ciation with the GTCT haplotype did not result from subtle population
stratification, we refit the model including the principal components of
genotypes from 73 ancestry informative markers (AIMs) from a published
panel of European substructure AIMs (Tian et al., 2008). Inclusion of the
first four principal components from the AIM genotypes as covariates in
the analyses did not substantially diminish the strength of the association.
For the 1242 individuals for whom AIMs were available, a similar associa-
tion between the GTCT haplotype and longevity was observed before
(OR = 1.47, P = 0.00039) and after (OR = 1.46, P = 0.00060) inclusion
of the principal components. Although a Tracy–Widom test (Patterson
et al., 2006) suggested that four principal components was sufficient to
account for potential population stratification, the observed result was
robust to the number of principal components included in the model
(P ranged from 0.00057 to 0.00062 when 1–10 principal components
were included). Similarly, the top two principal components from gen-
ome-wide data were available for 671 of the NECS individuals; inclusion
of these components as covariates in the analysis slightly strengthened
the result. In both cases, the inclusion of principal components in the
analyses affected the results only minimally, suggesting that the observed
haplotype association in the Stage 1 and NECS samples is not driven by
population stratification. Similarly, analysis of the first two principal com-
ponents did not reveal evidence of population stratification in a genome-
wide study of SICS cases and controls (Malovini et al., 2011). The French
sample had been previously tested for population stratification on 57
randomly selected microsatellite markers. As described in Supporting
Table 2 Trend test and meta-analysis
P-values for SNPs across five samples
SNP Ref SNP ID
Stage 1
(N = 1316)
NECS
(N = 738)
French
(N = 1103)
SICS
(N = 905)
Ashkenazi Jewish
(N = 702)
Meta-
analysis
1 rs2275075 0.54 0.73 0.78
2 rs3814314 0.017 0.81 0.039
3 rs11578696 0.21 0.93 0.39
4 rs4661146 0.12 0.17 0.42 0.65 0.72 0.97
5 rs10737170 0.11 0.016 0.84 0.54 0.45 0.075
6 rs915179 0.014 0.0086 0.96 0.66 0.59 0.020
7 rs2485662 0.054 0.11 0.81 0.82 0.35 0.026
8 rs547915 0.11 0.84 0.84 0.29
9 rs582690 0.078 0.42 0.35
10 rs6686943 0.51
11 rs508641 0.014 0.95 0.044
12 rs12117552 0.21 0.26 0.71
13 rs4641 0.50 0.14 0.61 0.30 0.45 0.98
14 rs12063072 0.36 0.060 0.065
15 rs1468772 0.034 0.35 0.41 0.14 0.0056
16 rs6669212 0.041 0.48 0.36 0.18
NECS, New England Centenarian Study; SICS, Southern Italian Centenarian Study.
Table 3 Meta-analysis of haplotype GTCT on
SNPs 6, 7, 13, and 15 across five samples Sample N Case Control OR Z statistic P-value Adjusted P-value
Stage 1 1316 0.235 0.163 1.56 4.21 0.000025 0.0045 (single-stage)
NECS 738 0.239 0.163 1.60 3.05 0.0023
French 1103 0.208 0.207 1.01 0.074 0.94
SICS 905 0.175 0.157 1.14 1.05 0.29
Ashkenazi 702 0.114 0.139 0.80 )1.40 0.16
Full meta-analysis 1.18 3.37 0.00075 0.037 (two-stage)
NECS, New England Centenarian Study; SICS, Southern Italian Centenarian Study.
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Information, v2 £ 1.00 in all cases, indicating that the French LLI and con-
trols were well matched.
Discussion
We observed evidence for association with longevity involving a 4-SNP
haplotype, and an excess of significant associations among the same set
of correlated haplotypes, in an initial sample of centenarians and younger
controls. This result was replicated in one of four follow-up samples, and
the association was sufficiently strong in those two samples to remain sig-
nificant when combined in a meta-analysis of all five.
Had our initial haplotype association been unreplicated in all four fol-
low-up samples, it would have been difficult to argue against the possibil-
ity of a false positive. However, the probability of observing a second
false positive of similar strength is low (< 0.005): in the same 10 000 per-
mutations used to adjust the meta-analysis P-value for multiple testing,
the best haplotype observed in the Stage 1 sample was followed up with
an association in the same direction with |Z| > 3.05 in one or more of the
four follow-up samples only 46 times.
Other possible explanations for incomplete replication include unde-
tected population structure, use of under-powered replication samples,
and heterogeneity between samples. However, adjustment for potential
population stratification via principal components only modestly dimin-
ished the associations reported here. Similarly, differential power based
on sample size differences does not appear to explain the incomplete rep-
lication as the NECS sample was arguably the least well-powered owing
to small sample size and skewed case–control ratio. Heterogeneity
between samples can occur for a variety of reasons. For example, the
GTCT haplotype could tag a functional variant in some samples but not
others owing to differential LD patterns. Alternatively, a functional variant
tagged by GTCT could correlate with the longevity phenotype only in the
NECS and Stage 1 samples; this can result from differential ascertainment
of cases or from between-sample differences in environmental exposures
(McCarthy et al., 2008). One potential source of heterogeneity is differ-
ential ascertainment of LLI, as the minimum age for inclusion varied by
study (Table 1). Notably, the association with GTCT was observed in two
of the three samples that had ascertained older sets of LLI (mean age >
100); Tan et al. (2008) has argued that the power of association studies
investigating exceptional longevity markedly increases with the use of
centenarian subjects compared to nonagenarians. However, in the four
samples where individual ages were available, we observed similar results
when the definition for cases was narrowed to include only centenarians.
Another potential source of heterogeneity is environmental differences
across samples owing to region of origin. The association between GTCT
and longevity was observed in two of the three US samples, but not in
the European samples. One region-specific environmental exposure that
could interact with aging-related genes to affect longevity is diet. Dietary
differences between Europe and the US have been proposed as explana-
tions for regional differences in rates of coronary mortality (Renaud & de
Lorgeril, 1992; de Lorgeril et al., 1994), and caloric restriction and several
dietary antioxidants, including resveratrol, found in red wine, can alter
expression of aging-related genes in the hearts and brains of mice (Park
et al., 2009).
Replicating genetic association results across diverse populations has
generally been difficult in the longevity literature (Christensen et al.,
2006). For example, a strong association between longevity and a
FOXO3A SNP (Willcox et al., 2008) replicated in some samples (Flachsbart
et al., 2009; Li et al., 2009), including men from the SICS (Anselmi et al.,
2009), but was not present in others (Kuningas et al., 2007) (Paw-
likowska et al., 2009; Soerensen et al., 2010), including women from the
SICS (Anselmi et al., 2009), although two of these studies reported asso-
ciations with other FOXO3A SNPs. Reasons proposed for the lack of repli-
cation in some samples included those discussed above, as well as lack of
gender stratification in some analyses (Anselmi et al., 2009), although, as
described in Results, this does not appear to be an issue in the present
study.
The meta-analysis results presented here complement a growing body
of experimental evidence (Scaffidi & Misteli, 2006; McClintock et al.,
2007; Cao et al., 2011) in suggesting a potential role for LMNA and prog-
erin in aspects of normal aging. However, given the incomplete replica-
tion we observed, further work is needed to validate and interpret the
results reported here. One of the four SNPs in our reported haplotype,
rs4641, is a coding SNP for which allele-specific expression has been dem-
onstrated (Rodriguez & Eriksson, 2011), with 2.3-fold greater expression
for transcripts with the C allele, which is part of the GTCT haplotype asso-
ciated with greater longevity in our meta-analysis. Another SNP in our
reported haplotype, rs915179, associated with longevity in a recent gen-
ome-wide association study (Sebastiani et al., 2012), although this study
included most of our NECS cases and controls along with other subjects.
Additional association studies of LMNA variants in independent samples
and additional experiments focusing on functional consequences of the
associated variants would be particularly valuable in establishing and elu-
cidating the role of LMNA in the normal aging process.
Experimental procedures
Samples
We analyzed one initial (Stage 1) and four follow-up (Stage 2) samples of
LLI and younger controls. Samples collected for the Stage 1 study by Elixir
Pharmaceuticals were Caucasians primarily of Northern European ances-
try. Samples were also obtained from the New England (NECS), French,
Southern Italian (SICS), and Ashkenazi Jewish Centenarian Studies.
Details of sample collection, as well as steps taken to ensure that the
study samples did not overlap, can be found in Supporting information.
Fig. 2 Forest plot of odds ratios for meta-analysis of haplotype GTCT on SNPs 6, 7,
13, and 15 across five samples. For each subsample, the black box is centered at the
estimated odds ratio, and the gray line represents a 95% confidence interval. Area
of the black box varies in proportion to the precision of each estimate. For the
meta-analysis, the black diamond is centered at the estimated odds ratio and spans
the 95% confidence interval for the meta-analysis odds ratio.
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SNP selection
We downloaded all SNP genotype data for the CEU population from
)40 kb to +10 kb of LMNA from the website of the International Hap-
Map (International HapMap Consortium 2005): http://www.hapmap.org.
These genotype data in raw HapMap format were uploaded to Tagger
(http://www.broad.mit.edu/mpg/tagger/), and our multiplex assay design
(see Supporting Information for details) was created from the list of tag
SNPs to capture all variants of interest in our LMNA region of interest. We
used r2 > 0.8 as the threshold for accepting tag SNPs. Ten SNPs were
selected in HapMap Phase I, release #16 along with the synonymous cod-
ing SNP, rs4641, which was not in HapMap Phase I. Upon release of Hap-
Map Phase II, release #19 we selected SNPs in the LMNA region again
and added five additional SNPs not tagged (r2 < 0.8) by the previously
selected SNPs. Based on Phase II of the HapMap, these 16 SNPs offered
comprehensive coverage and representation of common variants in the
LMNA region and were genotyped in Stage 1.
For Stage 2 samples, we genotyped the six SNPs from the most signifi-
cant 6-SNP haplotype in Stage 1. Additional SNPs from the original 16
were genotyped in some Stage 2 samples based on convenience; these
SNPs were tested for association (Table 2), but were not included in the
haplotype analysis. Details on SNP genotyping are provided in Supporting
information.
Statistical analysis
We used the MaCH 1.0 haplotype inference and imputation software (Li
et al., 2010) to infer 16-SNP haplotypes for all individuals in Stage 1 and
6-SNP haplotypes for all individuals in Stage 2. For individuals with miss-
ing genotypes, the most likely genotype was inferred based on haplotype
frequencies within the sample. We imputed genotypes for SNP
rs1468772 that was not genotyped in the French sample, using MaCH
(Li et al., 2010) in conjunction with phased haplotype information from
the HapMap CEU sample.
Weperformedassociation tests inallfive samplesandcombinedthesam-
ples in a meta-analysis using R (R Development Core Team 2011). We per-
formed all SNP and haplotype association tests as Cochran–Armitage tests
(Cochran, 1954;Armitage, 1955) for a linear trendbetween the number of
copies of a reference allele (0, 1, or 2) and the likelihood that an individual
belongs to the case or control group.We first tested each SNPor haplotype
for association with centenarian status. We computed meta-analysis
statistics for all followed-up SNPs and haplotypes as the weighted sum of
z-statistics from the trend tests. The weights for sample i were defined asﬃﬃﬃ
ni
n
q
,whereni = samplesize forsamples i = 1,…,5andn ¼
P5
i¼1
ni .
To account for the testing of multiple correlated SNPs and haplotypes
in Stage 1, we performed permutation tests by (i) randomly permuting
case–control status and (ii) recomputing the test statistics for all SNPs and
haplotypes. Based on 10 000 permutations, we then computed adjusted
P-values that reflected the probability of observing each result by chance
alone. To establish whether our most extreme P-value was significantly
different than what would be expected if no true association existed, we
computed an empirical P-value as the proportion of permutations in
which a more extreme result was observed in any of the SNPs or haplo-
types analyzed. To establish whether a significant excess of haplotypes
with P < a was observed for a given a-level, we computed empirical
P-values as the proportion of permutations in which we observed as many
haplotypes with P < a as in our original data.
To account for multiple testing in the two-stage analysis, we performed
permutation tests in R to obtain an empirical P-value for the best observed
meta-analysis test statistic. Permutation tests for two-stage studies are
complicated by the fact that only partial genotyping is performed in the
second stage of the study. Our strategy for dealing with this was, for per-
mutation purposes only, to use MaCH 1.0, along with inferred haplotypes
from the HapMap CEU sample, to impute the full 16-SNP haplotypes for
all Stage 2 samples. We were then able to perform a full two-stage analy-
sis in each permutation as follows:
1 Randomly reassign case–control status within each of the five
samples.
2 Compute trend test statistics for all haplotypes (or SNPs) in the
permuted Stage 1 sample.
3 To mimic the selection of six SNPs for genotyping in the Stage 2
samples, as was performed in the original study, select the most signifi-
cant 6-SNP haplotype from the (permuted) Stage 1 analysis for follow-up.
Perform trend tests of association for all six SNPs and for all haplotypes
composed of 2–6 SNP combinations of these six SNPs in the four per-
muted Stage 2 samples.
4 Compute meta-analysis statistics for all haplotypes (or SNPs) tested
on all five permuted samples; record the value of the most significant
meta-analysis test statistic.
We performed 10 000 permutations, and recorded the best meta-
analysis test statistic for each permutation. We computed the empirical
P-value as the proportion of permutations in which the best statistic from
the permutation was greater in magnitude than the best statistic from
the original data analysis.
Population stratification
As described in Supporting Information, the Stage 1 and French samples
had previously been tested for the presence of population stratification
between LLI and control subjects and the Stage 1 sample had been genet-
ically matched. There was no evidence of population stratification in the
French sample (mean v2 = 1.00 across 57 randommicrosatellite markers)
or in the genetically matched Stage 1 sample (mean v2 = 0.95 across 80
random SNPs) (Geesaman et al., 2003).
For the Stage 1 sample, we also genotypedAIMs from a published panel
specific to European genetic substructure (Tian et al., 2008); genotyping
and quality control are described in Supporting Information. We used R to
compute principal components and to identify the most important
principal components via a Tracy–Widom test (Patterson et al., 2006). To
perform an analysis adjusted for population stratification, we included the
top principal components as covariates in the original analysis.
Principal components based on genotypes from the 370K Illumina SNP
chip (collected as part of a separate study – Sebastiani et al., 2012) were
available for a subset of the NECS sample. We used EIGENSTRAT (Price et al.,
2006) to compute the principal components and identified the principal
components that were most informative based on visual inspection of a
scree plot. To perform an analysis adjusted for population stratification,
we included the top principal components as covariates in the original
analysis.
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